Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Weller

Showing results (391-400 of 940) with videos related to

Pageof 94
Sort By:
Antibody Therapeutics|November 11, 2025
Generation and characterization of novel high-affinity fully human antibodies targeting prostate-specific membrane antigen and prostatic acid phosphataseClaudia Comacchio, Stefanie K Pfister, Domenico Ravazza, et al.
Journal of Neuro-Oncology|June 14, 2016
Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphomaFelicitas Strehlow, Sandra Bauer, Peter Martus, et al.
Neuro-Oncology|February 12, 2016
68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?Michael Sommerauer, Jan-Karl Burkhardt, Karl Frontzek, et al.
Scientific Reports|October 17, 2019
Lymphatic outflow of cerebrospinal fluid is reduced in gliomaQiaoli Ma, Felix Schlegel, Samia B Bachmann, et al.
International Journal of Cancer|September 14, 2011
2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor sizeDavid Capper, Matthias Simon, Claus-Dieter Langhans, et al.
Journal of Neuro-Oncology|October 21, 2009
Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT statusDelia Kurzwelly, Martin Glas, Patrick Roth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2008
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activityMonika E Hegi, Lili Liu, James G Herman, et al.
Neuro-Oncology|May 28, 2010
Defective p53 antiangiogenic signaling in glioblastomaBenjamin Berger, David Capper, Dieter Lemke, et al.
Scientific Reports|March 5, 2025
An effective MRI perfusion threshold based workflow to triage additional <sup>18</sup>F-FET PET in posttreatment high grade gliomaKrishna Ranjith Kadali, Nathalie Nierobisch, Fabienne Maibach, et al.
Pharmacoepidemiology and Drug Safety|July 21, 2011
Evaluation of drug interactions and dosing in 484 neurological inpatients using clinical decision support software and an extended operational interaction classification system (Zurich Interaction System)Markus Guzek, Olesya I Zorina, Alexander Semmler, et al.
Pageof 94

Showing results (391-400 of 940) with videos related to

Sort By:
Pageof 94
Antibody Therapeutics|November 11, 2025
Generation and characterization of novel high-affinity fully human antibodies targeting prostate-specific membrane antigen and prostatic acid phosphataseClaudia Comacchio, Stefanie K Pfister, Domenico Ravazza, et al.
Journal of Neuro-Oncology|June 14, 2016
Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphomaFelicitas Strehlow, Sandra Bauer, Peter Martus, et al.
Neuro-Oncology|February 12, 2016
68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?Michael Sommerauer, Jan-Karl Burkhardt, Karl Frontzek, et al.
Scientific Reports|October 17, 2019
Lymphatic outflow of cerebrospinal fluid is reduced in gliomaQiaoli Ma, Felix Schlegel, Samia B Bachmann, et al.
International Journal of Cancer|September 14, 2011
2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor sizeDavid Capper, Matthias Simon, Claus-Dieter Langhans, et al.
Journal of Neuro-Oncology|October 21, 2009
Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT statusDelia Kurzwelly, Martin Glas, Patrick Roth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2008
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activityMonika E Hegi, Lili Liu, James G Herman, et al.
Neuro-Oncology|May 28, 2010
Defective p53 antiangiogenic signaling in glioblastomaBenjamin Berger, David Capper, Dieter Lemke, et al.
Scientific Reports|March 5, 2025
An effective MRI perfusion threshold based workflow to triage additional <sup>18</sup>F-FET PET in posttreatment high grade gliomaKrishna Ranjith Kadali, Nathalie Nierobisch, Fabienne Maibach, et al.
Pharmacoepidemiology and Drug Safety|July 21, 2011
Evaluation of drug interactions and dosing in 484 neurological inpatients using clinical decision support software and an extended operational interaction classification system (Zurich Interaction System)Markus Guzek, Olesya I Zorina, Alexander Semmler, et al.
Pageof 94